Compare Stocks: KROS, ACRS, RIGL, and FDMT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$6.01	$5.65	$1.74 ▼ $6.60	$840.32M	0.78	1.94 million shs	1.22 million shs
FDMT 4D Molecular Therapeutics	$14.67	$12.21	$5.97 ▼ $16.93	$810.37M	2.73	1.04 million shs	1.10 million shs
KROS Keros Therapeutics	$11.03	$10.78	$9.69 ▼ $22.55	$218.73M	0.99	223,647 shs	328,287 shs
RIGL Rigel Pharmaceuticals	$46.48	$40.73	$24.95 ▼ $52.24	$859.88M	1.16	347,995 shs	246,113 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	0.00%	-6.24%	+15.58%	+38.48%	+211.40%
FDMT 4D Molecular Therapeutics	0.00%	-7.33%	+44.11%	+51.08%	+138.15%
KROS Keros Therapeutics	0.00%	0.00%	+9.53%	+1.19%	-27.48%
RIGL Rigel Pharmaceuticals	0.00%	+1.29%	+26.27%	+55.66%	+19.64%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$6.01	$5.65	$1.74 ▼ $6.60	$840.32M	0.78	1.94 million shs	1.22 million shs
FDMT 4D Molecular Therapeutics	$14.67	$12.21	$5.97 ▼ $16.93	$810.37M	2.73	1.04 million shs	1.10 million shs
KROS Keros Therapeutics	$11.03	$10.78	$9.69 ▼ $22.55	$218.73M	0.99	223,647 shs	328,287 shs
RIGL Rigel Pharmaceuticals	$46.48	$40.73	$24.95 ▼ $52.24	$859.88M	1.16	347,995 shs	246,113 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	0.00%	-6.24%	+15.58%	+38.48%	+211.40%
FDMT 4D Molecular Therapeutics	0.00%	-7.33%	+44.11%	+51.08%	+138.15%
KROS Keros Therapeutics	0.00%	0.00%	+9.53%	+1.19%	-27.48%
RIGL Rigel Pharmaceuticals	0.00%	+1.29%	+26.27%	+55.66%	+19.64%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.13	Buy	$11.50	91.35% Upside
FDMT 4D Molecular Therapeutics	2.80	Moderate Buy	$29.63	101.94% Upside
KROS Keros Therapeutics	2.33	Hold	$20.50	85.86% Upside
RIGL Rigel Pharmaceuticals	2.43	Hold	$59.00	26.94% Upside

Current Analyst Ratings Breakdown

Latest KROS, ACRS, RIGL, and FDMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	KROS Keros Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/25/2026	RIGL Rigel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/17/2026	FDMT 4D Molecular Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	RIGL Rigel Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$40.00 ➝ $49.00
8/17/2026	RIGL Rigel Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/14/2026	RIGL Rigel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$57.00 ➝ $85.00
8/13/2026	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$32.00
8/12/2026	KROS Keros Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/6/2026	RIGL Rigel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/6/2026	RIGL Rigel Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/4/2026	KROS Keros Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$20.00 ➝ $18.00

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$7.83M	107.32	N/A	N/A	$0.85 per share	7.07
FDMT 4D Molecular Therapeutics	$85.21M	9.51	N/A	N/A	$8.85 per share	1.66
KROS Keros Therapeutics	$244.06M	0.90	$4.52 per share	2.44	$15.51 per share	0.71
RIGL Rigel Pharmaceuticals	$294.28M	2.92	$6.75 per share	6.89	$21.57 per share	2.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$64.92M	-$0.58	N/A	N/A	N/A	-921.50%	-61.65%	-42.41%	11/5/2026 (Estimated)
FDMT 4D Molecular Therapeutics	-$140.11M	-$2.63	N/A	N/A	N/A	-194.74%	-41.33%	-35.90%	11/10/2026 (Estimated)
KROS Keros Therapeutics	$87.01M	-$3.70	N/A	N/A	N/A	-256.60%	-21.40%	-19.79%	11/4/2026 (Estimated)
RIGL Rigel Pharmaceuticals	$367.02M	$16.32	2.85	10.76	N/A	116.30%	22.95%	17.19%	11/3/2026 (Estimated)

Latest KROS, ACRS, RIGL, and FDMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	FDMT 4D Molecular Therapeutics	-$1.02	-$1.04	-$0.02	-$1.04	$3.62 million	$3.78 million
8/6/2026	Q2 2026	ACRS Aclaris Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	$1.38 million	$1.63 million
8/4/2026	Q2 2026	RIGL Rigel Pharmaceuticals	$0.0877	$0.88	+$0.7923	$0.88	$55.28 million	$78.70 million
8/3/2026	Q2 2026	KROS Keros Therapeutics	-$1.34	-$1.45	-$0.11	-$1.45	$0.81 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	3.46	3.46
FDMT 4D Molecular Therapeutics	0.05	8.03	8.03
KROS Keros Therapeutics	N/A	21.96	21.96
RIGL Rigel Pharmaceuticals	N/A	1.94	1.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
FDMT 4D Molecular Therapeutics	99.27%
KROS Keros Therapeutics	71.56%
RIGL Rigel Pharmaceuticals	66.23%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	4.80%
FDMT 4D Molecular Therapeutics	7.90%
KROS Keros Therapeutics	12.60%
RIGL Rigel Pharmaceuticals	10.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	139.82 million	133.11 million	Optionable
FDMT 4D Molecular Therapeutics	120	55.24 million	50.88 million	Optionable
KROS Keros Therapeutics	100	19.83 million	17.33 million	Optionable
RIGL Rigel Pharmaceuticals	160	18.50 million	16.57 million	Optionable

KROS, ACRS, RIGL, and FDMT Headlines

Recent News About These Companies

Connor Clark & Lunn Investment Management Ltd. Buys Shares of 49,096 Rigel Pharmaceuticals, Inc. $RIGL

August 30 at 3:37 AM | marketbeat.com

Bank of America Corp DE Has $3.90 Million Stock Holdings in Rigel Pharmaceuticals, Inc. $RIGL

August 30 at 3:19 AM | marketbeat.com

OMERS ADMINISTRATION Corp Invests $2.03 Million in Rigel Pharmaceuticals, Inc. $RIGL

August 27, 2026 | marketbeat.com

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Average Rating of "Moderate Buy" by Brokerages

August 26, 2026 | marketbeat.com

Globeflex Capital L P Takes Position in Rigel Pharmaceuticals, Inc. $RIGL

August 24, 2026 | marketbeat.com

HC Wainwright Issues Optimistic Forecast for RIGL Earnings

August 20, 2026 | americanbankingnews.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Rating Increased to Hold at Zacks Research

August 19, 2026 | marketbeat.com

HC Wainwright Analysts Increase Earnings Estimates for RIGL

August 18, 2026 | marketbeat.com

Rigel Pharmaceuticals

August 17, 2026 | money.usnews.com

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

August 13, 2026 | prnewswire.com

Rigel Pharmaceuticals, Inc. $RIGL Shares Purchased by Dimensional Fund Advisors LP

August 10, 2026 | marketbeat.com

Janus Henderson Group PLC Boosts Position in Rigel Pharmaceuticals, Inc. $RIGL

August 8, 2026 | marketbeat.com

HC Wainwright Issues Pessimistic Estimate for RIGL Earnings

August 7, 2026 | marketbeat.com

Pacer Advisors Inc. Purchases 48,882 Shares of Rigel Pharmaceuticals, Inc. $RIGL

August 7, 2026 | marketbeat.com

HC Wainwright Issues Pessimistic Forecast for RIGL Earnings

August 6, 2026 | marketbeat.com

Empowered Funds LLC Takes Position in Rigel Pharmaceuticals, Inc. $RIGL

August 6, 2026 | marketbeat.com

Rigel Pharmaceuticals en quête d'acquisitions

August 5, 2026 | zonebourse.comZ

Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead

August 5, 2026 | seekingalpha.com

Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)

August 5, 2026 | seekingalpha.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap Up on Earnings Beat

August 5, 2026 | marketbeat.com

Rigel: Q2 Earnings Snapshot

August 4, 2026 | aol.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS, ACRS, RIGL, and FDMT Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$6.01 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

4D Molecular Therapeutics NASDAQ:FDMT

$14.67 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Keros Therapeutics NASDAQ:KROS

$11.03 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Rigel Pharmaceuticals NASDAQ:RIGL

$46.48 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KROS, ACRS, RIGL, and FDMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KROS, ACRS, RIGL, and FDMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KROS, ACRS, RIGL, and FDMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS, ACRS, RIGL, and FDMT Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

4D Molecular Therapeutics NASDAQ:FDMT

Keros Therapeutics NASDAQ:KROS

Rigel Pharmaceuticals NASDAQ:RIGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KROS, ACRS, RIGL, and FDMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KROS, ACRS, RIGL, and FDMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KROS, ACRS, RIGL, and FDMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS, ACRS, RIGL, and FDMT Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

4D Molecular Therapeutics NASDAQ:FDMT

Keros Therapeutics NASDAQ:KROS

Rigel Pharmaceuticals NASDAQ:RIGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools